Results 281 to 290 of about 816,685 (307)

Soluble IL‐2 receptors in acute and subacute encephalitis

Annals of Neurology, 1987
AbstractElevated levels of soluble interleukin‐2 receptors were present in the serum from patients with acute primary and postinfectious encephalitis and subacute sclerosing panencephalitis. In addition, soluble interleukin‐2 receptors were detected in the cerebrospinal fluid from patients with acute primary encephalitis.
D L Nelson, P Lebon, Gérard Ponsot, Arthuis M, L. Matsuguchi, B Boutin   +5 more
openaire   +2 more sources

Structural Studies of T200 Glycoprotein and the Il-2 Receptor

Journal of Receptor Research, 1987
Immunological analysis of the cell surface of hematopoietic cells has led to the identification of many different cell membrane molecules, some of which have well-defined functions as receptors. In general, however, the role of most lymphocyte cell surface molecules remains ill-defined even in cases in which antibody inhibition studies have given some ...
S. Ralph, D. Shackelford, M. Thomas, Ian S. Trowbridge   +3 more
openaire   +3 more sources

Variations in serum soluble IL‐2 receptor concentration

Pediatric Allergy and Immunology, 1994
Soluble interleukin‐2 receptor (sIL‐2R) concentrations were measured in the sera of 18 healthy adult volunteers, 40 healthy children aged 5 months ‐ 16 years 8 months and cord blood from 10 babies, using two commercially available ELISA kits (T‐cell Sciences and Serotec).
Jane Warner, A. C. Jones, Jill A. Warner, C. R. Besley   +3 more
openaire   +3 more sources

T cells expressing IL-2 receptor in migraine.

Acta neurologica, 1991
We studied a group of migraine patients for circulating immune complexes, lymphocyte subpopulations, IgG4 and anti-IgG antibodies, before, after 4 hours and after 72 hours a specific challenge test. We found an increased incidence of circulating immune complexes. Total T cells showed a marked increase after challenge test.
openaire   +2 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly